Thursday, October 30, 2025
Facebook Linkedin Twitter
HomeTagsTumor Myeloid-Directed

Tumor Myeloid-Directed

Biotechnology

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

PR Newswire -
Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that it presented the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us | Terms & Conditions